NASDAQ: SYBX - Synlogic, Inc.

Rentabilité sur six mois: -12.64%
Secteur: Healthcare

Calendrier des promotions Synlogic, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States.

Plus de détails
Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase II clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Выручка 0.0022
EBITDA -0.0517
Число акций ао 0.0065 млрд
P/S 33.63
P/BV 0.4767
EV/EBITDA -1.42
Цена ао 1.78
ISIN US87166L1008
Сайт https://www.synlogictx.com
Валюта usd
IPO date 2015-10-01
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Changement de prix par jour: -0.1576% (1.5224)
Changement de prix par semaine: -0.6536% (1.53)
Changement de prix par mois: +2.7% (1.48)
Changement de prix sur 3 mois: +3.4% (1.47)
Changement de prix sur six mois: -12.64% (1.74)
Changement de prix par an: -47.77% (2.91)
Evolution du prix sur 3 ans: -52.2% (3.18)
Evolution du prix sur 5 ans: -49.16% (2.99)
Evolution des prix depuis le début de l'année: -18.28% (1.86)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 7.02 1
P/BV 0.5549 10
P/E 0 0
EV/EBITDA -0.3314 0
Total: 5.13

Efficacité

Nom Signification Grade
ROA, % -75.82 0
ROE, % -134.29 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.3371 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 53.23 7
Rentabilité Ebitda, % -5.79 0
Rentabilité EPS, % 447.18 10
Total: 4
Plus de détails

Établissements Volume Partager, %
NEA Management Company, LLC 2922774 25.09
Armistice Capital, LLC 1055000 9.06
FMR, LLC 258644 2.22
Vanguard Group Inc 188433 1.62
Alyeska Investment Group, L.P. 55872 0.48
Renaissance Technologies, LLC 54630 0.47
Geode Capital Management, LLC 44423 0.38
Harbor Capital Advisors, Inc. 30685 0.26
Fiduciary Trust Company (MA) 22352 0.19
Ikarian Capital, LLC 20448 0.18



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Antoine Awad Principal Executive Officer 580.33k 1980 (44 année)
Dr. Timothy K. Lu M.D., Ph.D. Co-Founder & Member of Scientific Advisory Board N/A 1981 (43 année)
Dr. James J. Collins Ph.D. Co-Founder & Member of Scientific Advisory Board N/A 1966 (58 années)
Ms. Mary Beth Dooley VP, Head of Finance and Principal Financial Officer & Principal Accounting Officer N/A 1981 (43 année)
Mr. Ajay Munshi Vice President of Corporate Development N/A
Ms. Molly Harper Chief Business Officer N/A 1977 (47 années)
Dr. Neal Sondheimer M.D., Ph.D. VP & Head of Clinical N/A
Dr. Mylene Perreault Ph.D. VP & Head of Research
Dr. Jose-Carlos Gutierrez-Ramos Ph.D. Advisor 1962 (62 année)

Adresse: United States, Cambridge. MA, 301 Binney Street - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.synlogictx.com